In Brief

An agent that improves survival in metastatic breast cancer patients has been launched. Herceptin (trastuzumab), a humanised monoclonal antibody, suppresses tumour growth in the 20-30 per cent of metastatic breast cancer patients who overproduce a growth factor called HER2. It binds HER2 receptors on the cancer cell surface so that ...

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here